neuro-nt10q.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one):
[ ] Form 10-K
[ ] Form 20-F
[ ] Form 11-K
[X] Form 10-QSB
[ ] Form 10-D
[ ] Form N-SAR
[ ]  Form N-CSR


For Quarter Ended:
June 30, 2007
     
[ ]
Transition Report on Form 10-K
  
[ ]
Transition Report on Form 20-F
  
[ ]
Transition Report on Form 11-K
  
[ ]
Transition Report on Form 10-Q
  
[ ]
Transition Report on Form N-SAR
  
     
 
For the Transition Period Ended:
  
 
 
Read attached instruction sheet before preparing form.  Please print or type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
 

PART I — REGISTRANT INFORMATION
 
NEUROLOGIX, INC.
Full Name of Registrant
 
 
Former Name if Applicable
 
 
Address of Principal Executive Office (Street and Number)
 
ONE BRIDGE PLAZA
City, State and Zip Code
 
FORT LEE, NEW JERSEY  07024

PART II— RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
 
 (a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
 
    [X]
 (b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 
 (c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.



PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Neurologix’s quarterly report on Form 10-QSB for the quarter ended June 30, 2007 was filed on August 15, 2007, one day after the date it was due under applicable rules.  The delay in filing was due to unanticipated technical difficulties experienced in formatting the document.  As a result, the inability to file in a timely manner could not be eliminated without unreasonable effort or expense.  Our Form 10-QSB was filed earlier today.





PART IV — OTHER INFORMATION

(1)           Name and telephone number of person to contact in regard to this notification

Marc L. Panoff
  
201
  
592-6451
(Name)
  
(Area Code)
  
(Telephone Number)

(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).   Yes  [X]     No  [ ]


(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
Yes  [X]      No [ ]

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
 
Reference is made to Neurologix’s quarterly report on Form 10-QSB for the quarter ended June 30, 2007, which was filed with the Securities and Exchange Commission on August 15, 2007, for a description of Neurologix’s results of operations for the period involved. Such quarterly report is incorporated herein by reference.
 
 
 
 
NEUROLOGIX, INC.
(Name of Registrant as Specified in Charter)
 
 
has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
 
Date
August 15, 2007
  
By:
 /s/ Marc L. Panoff
     
Name:
Marc L. Panoff
     
Title:
Chief Financial Officer, Secretary and Treasurer
         

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.


 
ATTENTION
  
Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)